ArticleInternational urology and nephrology2015
Characteristics of IgA nephropathy in advanced-age patients.
Article in International urology and nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- The Correlation Between Podocyte Senescence and the Clinicopathology in Elderly Patients with IgAN.Clinical interventions in aging · 2026Article
- Identification and Validation of Aging-Related Genes in IgA Nephropathy in the Asian Population.International journal of general medicine · 2025Article
- Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries.BMC nephrology · 2024Review
- Crescents proportions above 10% are associated with unfavorable kidney outcomes in IgA nephropathy patients with partial crescent formation.Renal failure · 2023Article
- Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy.Renal failure · 2022Article
- Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.Iranian journal of public health · 2019Review
- Clinical and histological features and therapeutic strategies for IgA nephropathy.Clinical and experimental nephrology · 2019Review
- Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.Clinical and experimental nephrology · 2016Article
- Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR).Clinical and experimental nephrology · 2016Article
- Primary glomerular diseases in the elderly.World journal of nephrology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe susceptible age for IgA nephropathy (IgAN) is <30 years. However, IgAN sometimes develops in people aged >60 years, and its characteristics remain unknown.
methodsWe divided 600 IgAN patients into three groups: advanced-age group (AAG, n=31, ≥60 years); middle-aged group (MAG, n=162, 40-59 years); and young-aged group (YAG, n=407, 20-39 years). We analyzed clinical and histological background, renal outcome, and risk of progression.
resultsIn the AAG, mean arterial pressure (MAP) and the number of hypertensive patients were significantly higher than in the YAG. Total protein, serum albumin, and estimated glomerular filtration rate were significantly lower, and blood urea nitrogen, proteinuria, and N-acetyl-β-D-glucosaminidase were significantly higher in the AAG than in MAG and YAG. In histological findings, interstitial fibrosis/tubular atrophy by Oxford classification and arteriosclerosis were more severe in the AAG than the in YAG. Renal survival rate analyzed by Kaplan-Meier method was significantly lower in the AAG (22.9%/19 years in the AAG vs. 69.2 and 84.9%/20 years in the MAG and YAG, p<0.0001). The patients who progressed to end-stage renal disease (ESRD) in the AAG had higher MAP and more severe proteinuria compared with the patients who did not progress to ESRD in the AAG.
conclusionsThe characteristics of IgAN in advanced-age were lower renal function, high levels of proteinuria, severe interstitial change, and arteriolosclerosis caused by glomerulopathy and concomitant diseases, such as hypertension, dyslipidemia, and hyperuricemia. Prognosis was poor, and >70% developed ESRD within 20 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.